Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ensysce Biosciences ( (ENSC) ) just unveiled an announcement.
At its annual meeting of stockholders held on January 7, 2026, Ensysce Biosciences, Inc. secured shareholder approval for several key corporate actions that collectively strengthen its capital structure, governance continuity and financial oversight. Investors approved the full issuance of common stock and the exercise of warrants previously issued to an investor to comply with Nasdaq Listing Rule 5635(d), authorized a substantial increase in shares available under the company’s 2021 Omnibus Incentive Plan from 121,457 to 721,457 to expand its capacity for equity-based compensation, elected two Class I directors, William Chang and Lee Rauch, to serve terms expiring at the 2028 annual meeting, and ratified Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, while a proposed adjournment authority was not brought to a vote.
The most recent analyst rating on (ENSC) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Ensysce Biosciences stock, see the ENSC Stock Forecast page.
Spark’s Take on ENSC Stock
According to Spark, TipRanks’ AI Analyst, ENSC is a Neutral.
Score is weighed down primarily by weak financial performance (shrinking TTM revenue, structurally negative margins, and ongoing cash burn) and a clearly bearish technical setup (price below all key moving averages with negative MACD). A positive financing event helps near-term runway, but valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on ENSC stock, click here.
More about Ensysce Biosciences
Ensysce Biosciences, Inc. is a publicly traded company listed on Nasdaq; based on the context of its use of stock incentive plans, equity issuance and typical small-cap biotech capital structures, it operates as a development-stage life sciences company that relies on stock-based compensation and capital markets access to fund its operations and growth.
Average Trading Volume: 210,179
Technical Sentiment Signal: Sell
Current Market Cap: $3.67M
For detailed information about ENSC stock, go to TipRanks’ Stock Analysis page.